2023-10-25 16:00Financial Performance - Basic earnings per share for the third quarter were CNY 0.71, a 36.54% increase compared to the same period last year[5] - The company's net profit attributable to shareholders for the year-to-date period increased significantly, leading to a basic earnings per share of CNY 1.91, up from CNY 0.93 in the previous year[17] - The total comprehensive income for the period was CNY 323,974,453.15, compared to CNY 113,155,858.77 in the same period last year[17] - The net profit attributable to shareholders for Q3 2023 was ¥121,568,232.09, reflecting a growth of 34.00% year-over-year[21] - The net profit attributable to shareholders for the year-to-date period was ¥326,802,993.69, which is a significant increase of 102.04% year-over-year[21] - The company reported a net profit of CNY 326,967,441.02 for the first three quarters of 2023, compared to CNY 166,259,426.07 in the same period of 2022, reflecting an increase of about 96.66%[41] Revenue and Sales Growth - The company's operating revenue for Q3 2023 was ¥668,887,006.49, representing an increase of 8.80% compared to the same period last year[21] - For the year-to-date period, the operating revenue reached ¥1,981,789,458.11, marking a 25.23% increase compared to the same period last year[21] - The company experienced a significant increase in sales of its medical beauty hyaluronic acid products, with revenue growth exceeding 50% compared to the previous year[25] - The company’s sales revenue for the first three quarters of 2023 was CNY 2,153,855,868.18, compared to CNY 1,688,544,097.45 in the same period of 2022, reflecting an increase of approximately 27.5%[42] Research and Development - The total R&D investment amounted to CNY 52,763,351.61, representing 7.89% of operating revenue, an increase of 0.65 percentage points year-on-year[5] - The proportion of R&D investment to operating revenue has shown a consistent upward trend, indicating a strong commitment to innovation[5] - Research and development expenses for the first three quarters of 2023 were CNY 154,154,668.27, compared to CNY 121,221,455.33 in the same period of 2022, marking an increase of about 27.2%[41] Cash Flow and Assets - The net cash flow from operating activities increased by 116.37% year-to-date, primarily due to significant growth in operating revenue[9] - The net cash flow from operating activities for the year-to-date period was ¥391,564,343.48, showing a growth of 116.37% compared to the previous year[21] - Cash and cash equivalents at the end of the reporting period were CNY 406,363,089.01, down from CNY 682,889,664.04 at the end of 2022, a decrease of approximately 40.43%[39] - The cash inflow from investment activities totaled CNY 1,089,423,627.13 for the current period, compared to CNY 990,170,755.22 in the previous period, indicating an increase of about 10.03%[37] Equity and Liabilities - Total assets at the end of the reporting period were CNY 7,089,426,530.74, reflecting a 2.86% increase from the end of the previous year[5] - The company reported a total equity attributable to shareholders of CNY 5,704,966,947.12, a 3.45% increase from the previous year[5] - The total liabilities as of September 30, 2023, were ¥1,011,068,562.86, compared to ¥990,013,737.98 at the end of the previous period[33] - The company’s total liabilities increased to CNY 3,715,795,672.92 as of September 30, 2023, from CNY 3,532,115,166.92 at the end of 2022, representing a growth of approximately 5.18%[39]